INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN

Core Viewpoint - A class action lawsuit has been filed against UroGen Pharma Ltd. regarding allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP if they purchased UroGen securities during the Class Period, with a deadline to apply as Lead Plaintiff by July 28, 2025 [2]. - The lawsuit centers on whether UroGen and its officers engaged in fraudulent activities related to their securities [2]. Group 2: FDA and Drug Approval - The FDA raised concerns about UroGen's bladder cancer drug UGN-102, stating that the trial's primary endpoints were difficult to interpret due to the lack of a concurrent control arm [4]. - The FDA recommended a randomized trial design to address these concerns multiple times [4]. - Following the FDA's briefing, UroGen's stock price fell by $2.54 per share (25.79%) to close at $7.31 on May 16, 2025 [5]. - On May 21, 2025, the Oncologic Drugs Advisory Committee voted against the approval of UGN-102, leading to a further decline in UroGen's stock price by $3.37 per share (44.7%) to close at $4.17 [5].